Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trialLore Vanderbeke, Nico Janssen, Dennis C. J. J. Bergmans et al.|Intensive Care Medicine|2021Cited by 98
The Genetic Risk for COVID-19 Severity Is Associated With Defective Immune ResponsesYunus Kuijpers, Cheng‐Jian Xu, Bowen Zhang et al.|Frontiers in Immunology|2022Cited by 10
Regulation of plasma soluble receptors of TNF and IL-1 in patients with COVID-19 differs from that observed in sepsisMuhammed D. Aksu, Athanasios Ziogas, Tijmen van der Ent et al.|Journal of Infection|2024Cited by 6